Form 4: BlackRock Health Sciences Director Sells Shares

A director at BlackRock Health Sciences Term Trust executed pre-planned sales of common stock totaling over 20,000 shares in December 2025.

Summary

• Robert W. Fairbairn, a Director of BlackRock Health Sciences Term Trust (BMEZ), reported sales of common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• On December 18, 2025, Fairbairn directly sold 10,294 shares of common stock at a price of $14.98 per share.
• On December 19, 2025, Fairbairn directly sold 0.422 shares of common stock at a price of $14.96 per share.
• Additionally, on December 18, 2025, 10,294 shares were indirectly sold by Fairbairn's spouse at $14.98 per share.
• On December 19, 2025, 0.422 shares were indirectly sold by Fairbairn's spouse at $14.96 per share.
• Following these transactions, Fairbairn's direct beneficial ownership of common stock is 0 shares, and indirect beneficial ownership by spouse is 0 shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to significant insider selling, even though it was pre-planned. Large sales by a director can sometimes be perceived as a lack of confidence, despite the 10b5-1 plan mitigating some of that concern.

Negatives

• A director and their spouse sold a significant number of shares, which could be interpreted negatively by some investors, despite being pre-planned.

Future Outlook

The filing does not contain forward-looking statements or guidance, as it reports past insider transactions.

Industry Context

Insider transactions, particularly sales, are routinely monitored by investors as they can sometimes signal management's perception of the company's future prospects or valuation. However, sales made under a Rule 10b5-1 plan are pre-scheduled and do not necessarily reflect new sentiment.

Stakeholder Impact

• Shareholders may view the director's sale of shares as a potential signal regarding the company's valuation or future prospects, which could influence their investment decisions.

Key Dates

Recommendation

While significant insider selling can be a negative signal, the transactions were executed under a Rule 10b5-1 plan, indicating they were pre-scheduled and not necessarily based on new, material non-public information. Without additional context on the company's fundamentals or other market factors, a 'hold' recommendation is appropriate, advising investors to monitor future developments rather than making an immediate 'buy' or 'sell' decision solely based on this Form 4.

Keywords

BlackRock Health Sciences Term Trust, BMEZ, Insider Selling, Form 4, Director, Stock Sale, Rule 10b5-1